Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Anti-Angiogenesis Therapy for High-Risk Oral Cavity Cancer
NCT00934739Phase 3Terminated
- Sponsor
- National Health Research Institutes
- Start
- Jun 2007
- Primary completion
- Dec 2012
- Modality
- Orthosteric Ligands
01
Overview
A Phase 3 trial of thalidomide, celecoxib in oral cavity squamous cell carcinoma (OCSCC), sponsored by National Health Research Institutes. Started Jun 2007; status: terminated.
02
Drugs
thalidomidecelecoxib
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT00934739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00934739.